{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05130437",
            "orgStudyIdInfo": {
                "id": "mRNA-3927-P101-EXT"
            },
            "secondaryIdInfos": [
                {
                    "id": "2020-005009-14",
                    "type": "EUDRACT_NUMBER"
                }
            ],
            "organization": {
                "fullName": "ModernaTX, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Long-Term Extension Study to Evaluate the Safety and Clinical Activity of mRNA-3927",
            "officialTitle": "A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-long-term-extension-study-to-evaluate-the-safety-and-clinical-activity-of-mrna"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-11-09",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2029-12-04",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2031-12-04",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-11-03",
            "studyFirstSubmitQcDate": "2021-11-18",
            "studyFirstPostDateStruct": {
                "date": "2021-11-23",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-27",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-28",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "ModernaTX, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The main purpose of this study is to evaluate the long-term safety of mRNA-3927 administered to participants with propionic acidemia (PA) who have previously participated in Study mRNA-3927-P101 (NCT04159103).",
            "detailedDescription": "The study will assess long-term safety and clinical activity of mRNA-3927. Participants with PA who were previously enrolled and completed the end-of-treatment (EOT) Visit of the mRNA-3927-P101 study will have the option to enroll into this extension study provided all eligibility criteria have been met.\n\nThe study will include 2 periods: 1) Treatment Period and 2) Follow-up Period (up to 2 years after the last dose of study drug). All participants will enter the study receiving mRNA-3927 at the same dose and at the same dosing interval last received in the mRNA-3927-P101 study."
        },
        "conditionsModule": {
            "conditions": [
                "Propionic Acidemia"
            ],
            "keywords": [
                "mRNA-3927",
                "Propionic Aciduria",
                "Metabolism, Inborn Errors",
                "Genetic Diseases",
                "Inborn Amino Acid Metabolism, Inborn Errors",
                "Acidosis",
                "Acid-Base Imbalance",
                "Metabolic Diseases",
                "Organic Acidemias",
                "Moderna",
                "mRNA"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 36,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "mRNA-3927",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive the applicable dose identified during Study mRNA-3927-P101 (NCT04159103) on Day 1. The dose can be adjusted based on Sponsor recommendation.",
                    "interventionNames": [
                        "Biological: mRNA-3927"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "mRNA-3927",
                    "description": "mRNA-3927 dispersion for IV infusion",
                    "armGroupLabels": [
                        "mRNA-3927"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of Participants with Treatment-Emergent Adverse Events (TEAEs)",
                    "timeFrame": "Baseline up to End of Study Visit (up to 8 years)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change From Baseline in Plasma 2-Methylcitrate (2-MC) Levels",
                    "timeFrame": "Baseline, End of Study (up to 8 years)"
                },
                {
                    "measure": "Change From Baseline in Plasma 3-Hydroxypropionic Acid (3-HP) Levels",
                    "timeFrame": "Baseline, End of Study (up to 8 years)"
                },
                {
                    "measure": "Pharmacokinetic (PK): Propionyl-CoA Carboxylase (PCC) Subunit \u03b1 (PCCA) and Propionyl-CoA Carboxylase Subunit \u03b2 (PCCB) mRNA (Serum) and SM-86 (Plasma) Levels",
                    "timeFrame": "Predose and End of Infusion up to 8 years postdose"
                },
                {
                    "measure": "Number of Clinically Significant Events",
                    "description": "Clinically significant events include hospitalization, emergency room visits, emergency interventions outside of healthcare settings, and complications of cardiomyopathy treated outside of hospital.",
                    "timeFrame": "Baseline up to 8 years"
                },
                {
                    "measure": "Number of Metabolic Decompensation Events (MDEs)",
                    "timeFrame": "Baseline up to 8 years"
                },
                {
                    "measure": "Number of Healthcare Resource Utilization Visits",
                    "timeFrame": "Baseline up to 8 years"
                },
                {
                    "measure": "Number of Days Participants Missed School and Workdays",
                    "timeFrame": "Baseline up to 8 years"
                },
                {
                    "measure": "Number of Anti-Polyethylene Glycol Antibodies",
                    "timeFrame": "Month 6 up to 8 years"
                },
                {
                    "measure": "Number of Anti-PCC Antibodies",
                    "timeFrame": "Month 6 up to 8 years"
                },
                {
                    "measure": "Change From Baseline in Pediatric Quality-of-Life Inventory (PedsQL)",
                    "timeFrame": "Baseline, End of Study (up to 8 years)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Participated in Study mRNA-3927-P101.\n* Completed the EOT Visit in Study mRNA-3927-P101 within 10 days of first dose of mRNA-3927 in current study.\n\nExclusion Criteria:\n\n* Not expected to receive clinical benefit from continued mRNA-3927 administration, in the opinion of the Investigator.\n* Any clinical or laboratory abnormality or medical condition that, at the discretion of the Investigator, may put the individual at increased risk by participating in this study.\n* History of liver and/or kidney transplant.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "1 Year",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Moderna Clinical Trials Support Center",
                    "role": "CONTACT",
                    "phone": "1-877-777-7187",
                    "email": "clinicaltrials@modernatx.com"
                }
            ],
            "locations": [
                {
                    "facility": "Michigan",
                    "status": "RECRUITING",
                    "city": "Ann Arbor",
                    "state": "Michigan",
                    "zip": "48109",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.27756,
                        "lon": -83.74088
                    }
                },
                {
                    "facility": "Duke University Medical Center",
                    "status": "RECRUITING",
                    "city": "Durham",
                    "state": "North Carolina",
                    "zip": "27710",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.99403,
                        "lon": -78.89862
                    }
                },
                {
                    "facility": "Children's Hospital of Philadelphia",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "Hospital For Sick Children",
                    "status": "RECRUITING",
                    "city": "Toronto",
                    "state": "Ontario",
                    "zip": "M5G 1X8",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 43.70011,
                        "lon": -79.4163
                    }
                },
                {
                    "facility": "University Hospital Birmingham NHS Foundation Trust",
                    "status": "RECRUITING",
                    "city": "Birmingham",
                    "zip": "B15 2TH",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 52.48142,
                        "lon": -1.89983
                    }
                },
                {
                    "facility": "Great Ormond Street Hospital (GOSH)",
                    "status": "RECRUITING",
                    "city": "London",
                    "zip": "WC1N 3JH",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 51.50853,
                        "lon": -0.12574
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000056693",
                    "term": "Propionic Acidemia"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000592",
                    "term": "Amino Acid Metabolism, Inborn Errors"
                },
                {
                    "id": "D000008661",
                    "term": "Metabolism, Inborn Errors"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M3499",
                    "name": "Acidosis",
                    "relevance": "LOW"
                },
                {
                    "id": "M11641",
                    "name": "Metabolism, Inborn Errors",
                    "relevance": "LOW"
                },
                {
                    "id": "M3932",
                    "name": "Amino Acid Metabolism, Inborn Errors",
                    "relevance": "LOW"
                },
                {
                    "id": "M28553",
                    "name": "Propionic Acidemia",
                    "asFound": "Propionic Acidemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3498",
                    "name": "Acid-Base Imbalance",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "T3036",
                    "name": "Inborn Amino Acid Metabolism Disorder",
                    "relevance": "LOW"
                },
                {
                    "id": "T4751",
                    "name": "Propionic Acidemia",
                    "asFound": "Propionic Acidemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4272",
                    "name": "Organic Acidemias",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}